US Patent Issued to Janssen Pharmaceuticals on Nov. 4 for "Recombinant arterivirus replicon systems and uses thereof" (California, Kansas Inventors)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,460,229, issued on Nov. 4, was assigned to Janssen Pharmaceuticals Inc. (Titusville, N.J.).

"Recombinant arterivirus replicon systems and uses thereof" was invented by Kurt Iver Kamrud (Olathe, Kan.), Nathaniel Stephen Wang (San Diego), Martina Felderman (La Jolla, Calif.) and Nancy C. Carrico (La Jolla, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RN...